Cancer Research and Treatment

Case Reports

Diffuse Large B-Cell Lymphoma Arising within Ileal Neobladder: An Expanding Spectrum of Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation: Hyekyung Lee, Hyunbin Shin, Nae Yu Kim, Hyun Sik Park, Jinsung Park; Cancer Res Treat. 2019;51(4):1666-1670. Published online March 22, 2019; DOI: https://doi.org/10.4143/crt.2019.022

Diffuse large B-cell lymphoma associated with chronic inflammation (DLBCL-CI), specifically arising in ileal neobladder, is a rare neoplasm. We present an unusual case of Epstein– Barr virus (EBV)–positive DLBCL-CI arising within neobladder with detailed clinical, histological, and immunophenotypical features in an immunocompetent patient. An 88-year-old male was admitted for gross hematuria. He had undergone radical cystectomy and ileal neobladder 17 years ago for invasive bladder cancer. Computed tomography showed enhancing lesions on dome and posterior wall of neobladder with mucosal thickening and multiple enlarged retroperitoneal lymphadenopathies. Transurethralresection of neobladder lesion revealed the diffuse infiltration of large lymphoid cells which were positive for CD20, CD30, and multiple myeloma oncogen-1 with EBV-encoded small RNAs co-localizing, and diagnosis of EBV-positive DLBCL-CI was made. After multi-agent chemotherapy, the lesion disappeared. We suggest that clinicians should consider the possibility of DLBCL-CI in patients presented with hematuria during follow-up after bladder reconstruction.

Citations

Citations to this article as recorded by

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma
Paola Chabay
Cancers.2021; 13(11): 2717. CrossRef

5,699 View
162 Download
1 Web of Science
1 Crossref

A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy: Bong Suk Ko, Nae Yu Kim, Ah Jung Ryu, Dong Soon Kim, Soo Jung Gong, Dae Kyung Kim, Hyun Jin Son, Jung-Ae Lee; Cancer Res Treat. 2012;44(3):210-214. Published online September 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.3.210

Abstract PDF PubReader ePub

A 50-year-old male patient presented with a right scrotal mass that had been growing rapidly for more than one year. A heterogeneous enhancing right scrotal mass (12x9 cm) with para-aortic and peri-caval lymphadenopathies was found on abdominal computed tomography (CT). Right orchiectomy was performed and the gross finding had shown intact testis with a well-defined, huge, whitish solid mass adjacent to the testis. According to pathology, the mass was characterized as a leiomyosarcoma, grade 3 (by National Cancer Instituted [NCI] system). Therefore, the diagnosis was stage III, grade 3 paratesticular leiomyosarcoma. The patient underwent additional systemic chemotherapy using ifosfamide and adriamycin. After nine cycles of chemotherapy, positron emission tomography-CT was performed and no FDP uptake was observed. The patient has been followed up for 12 months after systemic chemotherapy, and he has maintained a complete response. We report here on a rare case of paratesticular leiomyosarcoma treated successfully with orichiectomy and additional systemic chemotherapy.

Citations

Citations to this article as recorded by

Para-testicular Sarcoma: An Extreme Rarity
Anurag Mishra, Tridibes Mandal
Journal of Medical Evidence.2024;[Epub] CrossRef
Scrotal wall leiomyosarcoma: a case report and review of the literature
Zahra Erfani, Aileen Azari-yam, Seyed Reza Yahyazadeh
Journal of Medical Case Reports.2021;[Epub] CrossRef
Commentary on “A Case of Paratesticular Leiomyosarcoma Successfully Treated with Orchiectomy and Chemotherapy”
Edoardo Virgilio, Stefania Uccini, Paolo Marchetti, Paolo Mercantini
Cancer Research and Treatment.2016; 48(1): 422. CrossRef
Adult Urological Soft Tissue Sarcomas: A Multicenter Study of the Anatolian Society of Medical Oncology (ASMO)
Olcun Umit Unal, Ilhan Oztop, Serkan Menekse, Zuhat Urakci, Oktay Bozkurt, Melike Ozcelik, Yusuf Gunaydin, Nurgul Yasar, Dogan Yazilitas, Hilmi Kodaz, Burcu Yapar Taskoylu, Asude Aksoy, Umut Demirci, Murat Araz, Onder Tonyali, Alper Sevinc, Ahmet Ugur Yil
Asian Pacific Journal of Cancer Prevention.2015; 16(11): 4777. CrossRef
A Rare Case of Paratesticular Leiomyosarcoma
Shankar Haran, Vikram Balakrishan, Greg Neerhut
Case Reports in Urology.2014; 2014: 1. CrossRef

15,705 View
70 Download
5 Crossref

Original Article

Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era: Nae Yu Kim, Jong Mu Sun, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jin-Wook Kim, Sook-Hyang Jeong, Jong Seok Lee; Cancer Res Treat. 2010;42(4):203-209. Published online December 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.4.203

Abstract PDF PubReader ePub

Purpose

Systemic chemotherapy is the only option for patients with unresectable/metastatic hepatocellular carcinoma (HCC) who are not candidates for local/regional treatment. However, the response to such treatment and survival are poor, especially in hepatitis B virus (HBV) endemic areas. The aim of this study was to determine the efficacy of cisplatin-based combination chemotherapy and identify a subgroup of advanced HCC patients with favorable responses.

Materials and Methods

The medical records of all consecutive patients with unresectable/metastatic HCC who received cisplatin-based combination chemotherapy between January 2003 and October 2009 were reviewed. Time to progression (TTP) and overall survival (OS) were determined using Kaplan-Meier analysis. Univariate and multivariate analyses were performed to identify prognostic factors for TTP and OS.

Results

Data for 46 patients were analyzed. First-line chemotherapies consisted of cisplatin-based combination treatment with doxorubicin, fluoropyrimidines and gemcitabine. The response rate for all patients was 4.3%. The median TTP and OS were 1.8 (95%confidence interval [CI], 1.1 to 2.5) and 7.2 (95% CI, 3.0 to 11.5) months, respectively. Eastern Cooperative Oncology Group (ECOG) performance status (PS), Child classification, Cancer of the Liver Italian Program (CLIP) score and portal vein thrombosis (PVT) were identified by univariate analyses as prognostic factors for TTP and OS. ECOG PS (hazard ratio [HR], 4.51; 95% CI, 1.61 to 12.6; p=0.004) and PVT (HR, 2.12; 95% CI, 1.10 to 4.11; p=0.026) were independent prognostic factors for TTP.

Conclusion

Cisplatin-based combination chemotherapy in patients with advanced HCC has a low response rate and short TTP regardless of the chemotherapy regimen used. Patients with a good ECOG PS and without PVT can be considered candidates for cisplatin-based combination chemotherapy.

Citations

Citations to this article as recorded by

circ_HMGCS1 modulates hepatocellular carcinoma chemoresistance via miR‐338‐5p/IL‐7 pathway
Siyu Zhang, Jun Ma, Tingdong Yu, Zhengrui Song, Wan Yee Lau, Yong Zha
Journal of Cellular and Molecular Medicine.2024;[Epub] CrossRef
Inhibition of mycobacteria proliferation in macrophages by low cisplatin concentration through phosphorylated p53-related apoptosis pathway
Jiajia Bao, Yonglin He, Chun Yang, Nan Lu, Anlong Li, Sijia Gao, Felycia Fernanda Hosyanto, Jialing Tang, Junzhuo Si, Xia Tang, Huichao Fu, Lei Xu, Harish Chandra
PLOS ONE.2023; 18(1): e0281170. CrossRef
A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma
Yao‐Chung Liu, Chien‐Wei Su, Po‐Shen Ko, Rheun‐Chuan Lee, Chia‐Jen Liu, Yi‐Hsiang Huang, Jyh‐Pyng Gau, Jin‐Hwang Liu
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 19. CrossRef
A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy
Vincent Manceau, Xavier Palard, Yan Rolland, March Pracht, Samuel Le Sourd, Sophie Laffont, Karim Boudjema, Astride Lievre, Habiba Mesbah, Laure-Anne Haumont, Laurence Lenoir, Vanessa Brun, Thomas Uguen, Julien Edeline, Etienne Garin
European Journal of Nuclear Medicine and Molecular Imaging.2018; 45(10): 1731. CrossRef
Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1
Jun Qin, Meng Luo, Haixin Qian, Wei Chen
Gene.2014; 538(2): 342. CrossRef
The effects of fucodian on senescence are controlled by the p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma and hepatic cell lines
EUN-YOUNG MIN, IN-HYE KIM, JUNGIM LEE, EUN-YOUNG KIM, YOUN-HEE CHOI, TAEK-JEONG NAM
International Journal of Oncology.2014; 45(1): 47. CrossRef
The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation
Vasilis P. Androutsopoulos, Demetrios A. Spandidos
The Journal of Nutritional Biochemistry.2013; 24(2): 496. CrossRef
Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in Japan
Hiroki Nishikawa, Yukio Osaki, Ryuichi Kita, Toru Kimura
Cancers.2012; 4(1): 165. CrossRef

9,885 View
55 Download
8 Crossref

First
Prev
Page of 1
Next
Last

Search